Search
Protocol No.: A011801
- Title
- The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer): CompassHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
- Principal Investigator
- Kurian, Sobha
- Phase
- III
- Age Group
- Adult
- Applicable Disease Site
- Breast Cancer
- Participating Institutions
- Camden Clark Medical Center
- Mary Babb Randolph Cancer Center
- Contacts
- Emily Hawkins, BSN
- Research Nurse
- Phone: +1 304-293-7375
- Email: eswiger1@hsc.wvu.edu
- Layla Tannoury
- Clinical Research Specialist
- Phone: +1 304-424-2585
- Email: layla.tannoury@wvumedicine.org